ArticleCancers2021

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.

Julie E Bauman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.